INS and diabetes mellitus: In addition, the results of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial [10] would support the use of liraglutide vs. insulin as the preferred injectable treatment in the population of patients with established CVD (if glycemic control and/or comorbidity profile allowed for its use).